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Background: COPD is characterized by persistent and progressive airway inflammation. 
Although neutrophilic airway inflammation is generally accepted to be a major factor in the 
pathogenesis of COPD, the influence of the agents used for the treatment of COPD on neutrophil 
functions such as chemotaxis is not fully understood.
Purpose: The present study aimed to examine the influence of tiotropium bromide on the 
production of interleukin (IL)-8 from human airway epithelial cells and lung fibroblasts (LFs) 
after lipopolysaccharide (LPS) stimulation in vitro.
Methods: BEAS-2B cells, human bronchial epithelial cell line, and LFs, at a concentration 
of 5 × 105 cells/mL, were stimulated with LPS in the presence of various concentrations of 
tiotropium bromide. IL-8 in culture supernatants was examined by enzyme-linked immuno-
sorbent assay (ELISA). IL-8 messenger ribonucleic acid (mRNA) expression was examined 
by real-time polymerase chain reaction. The influence of tiotropium bromide on LPS-induced 
signaling pathways was also analyzed by examining nuclear factor-kappa (NF-κ)B activation 
and signaling protein phosphorylation by ELISA.
Results: Tiotropium bromide at .15 pg/mL inhibited IL-8 production from both BEAS-2B 
cells and LFs after LPS stimulation. Tiotropium bromide also suppressed IL-8 mRNA expression 
through the inhibition of NF-κB activation and signaling protein, extracellular-signal-regulated 
kinase 1/2, and c-Jun N-terminal kinase, phosphorylation.
Conclusion: The present results strongly suggest that tiotropium bromide exerts the inhibitory 
effect on neutrophilic inflammation through the suppression of IL-8 production from epithelial 
cells and LFs by interfering with LPS-mediated signaling pathways and thus may contribute 
to lower cellular inflammation in COPD, which is responsible for favorable modification of 
the disease.
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Introduction
COPD includes severe clinical conditions characterized by progressive airflow limitation.1 
The pathophysiology of airways in COPD involves neutrophilic airway inflammation, 
protease – antiproteases imbalance, and oxidative stress.2 Airway inflammation in COPD 
can be demonstrated by examination of sputum.2,3 Sputum from smokers and ex-smokers 
with COPD contained a much higher number of neutrophils than sputum from those without 
COPD, and increased neutrophils are associated with rapid decline in forced expiratory 
volume in 1 second (FEV1).4 It is also observed that the levels of myeloperoxidase and 
lactoferrin, which are the neutrophil activation makers, are elevated in the sputum from 
COPD patients.2,5 Although these reports strongly indicate that neutrophils are active International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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participants in airway inflammation in COPD, the influence 
of the agents used for the treatment of COPD on neutrophil 
functions such as chemotaxis is not well defined.
Anticholinergic agents have been proven to be of particular 
value in the treatment of COPD, as vagal cholinergic tone 
appears to be the only reversible component of airway 
narrowing.6 Anticholinergics block muscarinic receptors located 
on airway smooth muscle cells and possibly on submucosal 
gland cells, and prevent smooth muscle contraction and mucus 
secretion, thus producing a bronchodilatory effect.6 Tiotropium 
bromide, an anticholinergic bronchodilator, has a quaternary 
ammonium structure and is derived from that of ipratropium 
bromide.7 It has been clearly shown that tiotropium bromide 
was approximately 10-fold more potent than ipratropium in 
binding to cloned human muscarinic receptors expressed on 
Chinese hamster ovary cells. The apparent binding affinity of 
tiotropium bromide and ipratropium was similar for M1, M2, 
and M3 receptors, but kinetic studies showed that tiotropium 
bromide dissociated 100 times more slowly than ipratropium 
from M1 and M3.7 From these pharmacological studies, 
tiotropium bromide is recommended as the first-choice agent 
in the treatment of COPD.8
Interleukin (IL)-8, a member of the CXC chemokine 
family, is known to be produced by macrophages and 
other cells such as epithelial cells and fibroblasts. It is 
also recognized that IL-8 is involved in the development 
of several human conditions including wound repair, 
angiogenesis, and COPD.9 The primary function of IL-8 is 
the induction of chemotaxis in neutrophils and lymphocytes. 
The elevation of IL-8 in sputum levels in studies of stable 
COPD10,11 and the significant correlations between IL-8 levels 
in sputum and COPD severity as judged by FEV1
12 have 
been reported. Tiotropium bromide is reported to reduce 
neutrophil chemotaxis induced by the supernatant from 
alveolar macrophage stimulated with lipopolysaccharide 
(LPS) through the suppression of tumor necrosis factor-α 
production. However, the precise mechanisms are not well 
defined.13 In the present study, therefore, we examined 
the influence of the muscarinic receptor antagonists on 
IL-8 production from epithelial cells through the choice of 
tiotropium bromide, the most common muscarinic receptor 
antagonist, and an in vitro cell culture technique.
Materials and methods
Chemicals
Tiotropium bromide was kindly donated from   Nippon 
Boehringer Ingelheim Co, Ltd (Tokyo, Japan) as a preservative-
free pure powder. The powder was dissolved in Dulbecco’s 
Modified Eagle’s Medium/Ham’s Nutrient Mixture F-12 
(DMEM/F-12) medium (Sigma-Aldrich, Inc,   St Louis, MO; 
MEDIUM) at a concentration of 10.0 µg/mL. This solution 
was then sterilized by passing it through 0.2 µm filters and 
stored at 4°C as stock solution until used. All dilutions used 
in this study were prepared from this stock solution by dilut-
ing it with MEDIUM. LPS extracted from Escherichia coli 
(Sigma-Aldrich, Inc) was dissolved in MEDIUM at a con-
centration of 10.0 mg/mL. It was then sterilized by passing it 
through a 0.2 µm filter and diluted with MEDIUM at 3.0 µg/
mL. SP-600125, a c-Jun N-terminal kinase (JNK)-II inhibitor, 
PD-98059, a mitogen-activated protein kinases/extracellular-
signal-related kinase (MAPK/ERK), which is an upstream 
kinase of ERK1/2, inhibitor, and SB-203580, a p38 MAPK 
inhibitor, were purchased from Calbiochem (La Jolla, CA). 
These chemicals were first dissolved in dimethyl sulfoxide at 
1 mM, then diluted with MEDIUM at 10 µM, filtered through 
0.2 µm filters, and used for experiments.
Cell line
The human bronchial epithelial cell line BEAS-2B cells 
were purchased from American Type Culture Collection 
(Manassas, VA) and cultured in small airway cell basal 
medium (SABM®) that contained growth factors for epithelial 
cells (Lonza Co, Ltd, Walkersville, MD). The cells were used 
between the 45th and 55th generation passages.
Cell source and induction of fibroblasts
Tissue samples from patients without lung fibrosis or COPD 
were obtained from healthy tissue area during pneumonectomy 
for tumor resection from a tumor-free area. All donors (three 
female, 43–71 years; two male, 41 and 71 years) were given 
a written informed consent, which was approved by the 
Ethics Committee of Showa University Yokohama Northern 
Hospital. Cells were induced from tissues according to the 
methods described previously.13 Briefly, the diced tissue 
specimens (approximately 1 mm2) were plated at a density of 
10 pieces in 100-mm tissue culture dishes and covered with a 
microscope slide that adhered to the dishes. The dishes were 
then placed in a humidified atmosphere containing 5% CO2 
at 37°C. When a monolayer of fibroblast-like cells was found 
to be confluent, the explanted tissues were removed. The 
cells were then trypsinized, and replated at a concentration 
of 5 × 105 cells/mL into 100-mm tissue culture dishes with 
a final volume of 10.0 mL. Subsequently, the cells were split 
1:2 at confluence and passaged. The cells were characterized 
according to the methods described previously,14 and the 
fibroblast purity was more than 99% and used as lung-derived International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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fibroblasts (LFs). LFs at 5 to 6 passages were used for the 
experiments.
Cell culture
BEAS-2B cells were washed several times with MEDIUM 
and introduced into each well of 24-well culture plates in 
triplicate at a concentration of 5 × 105 cells/mL. After 12 hours, 
cells were treated with LPS and various concentrations of 
tiotropium bromide in a final volume of 2.0 mL. After 
24 hours, the culture supernatants were removed, and 
stored at -40°C until used. To examine transcription 
factor activation and messenger ribonucleic acid (mRNA) 
expression, BEAS-2B cells were cultured in a similar manner 
for 4 hours and stored at -80°C until used. To prepare cells 
to examine signaling protein phosphorylation, BEAS-2B 
cells were cultured in a similar manner with 96-well flat-
bottomed culture plates for 30 minutes. In experiments using 
LFs as target cells, LFs suspended in RPMI-1640 medium 
supplemented with 10% fetal calf serum (RPMI-FCS) were 
cultured in a similar manner to that used for BEAS-2B cells. 
In all cases, tiotropium bromide was added to cell cultures 
2 hours before the stimulation with LPS.
Assay for IL-8
IL-8 levels in culture supernatants were examined by the 
commercially available human IL-8 enzyme-linked immuno-
sorbent assay (ELISA) kits (R & D Systems, Inc, Minneapolis, 
MN) according to the manufacturer’s recommendation.
real-time polymerase chain reaction  
(rT-PCr)
IL-8 mRNA expression in both BEAS-2B cells and LFs were 
examined by RT-PCR according to the methods described 
previously.14 Oligonucleotide sequences of the primers used 
are shown in Table 1.
Assay for transcription factor activation
Nuclear factor-kappa (NF-κ)B activity in cultured cells was ana-
lyzed by commercially available NF-κB ELISA test kits (Active 
Motif, Carlsbad, CA) that contained sufficient reagents and 
monoclonal antibodies against p50 and p65, in accordance with 
the manufacturer’s recommended   procedures. In brief, nuclear 
extract (5.0 µg protein) from cells was introduced into each 
well of 96-well microplates pre-coated with oligonucleotide 
containing the NF-κB consensus site (5′-GGGACTTTCC-3′) 
in a volume of 20.0 µL, and incubated for 1 hour at 25°C. After 
washing three times, 100 µL of monoclonal antibody against 
p50 and p65 was added to the appropriate wells, and incubated 
for a further 1 hour at 25°C. Anti-IgG horseradish peroxidase 
(HRP)-conjugate in a volume of 100 µL was then added and 
incubated for 1 hour at 25°C. The absorbance at 450 nm was 
measured after the addition of tetramethylbenzine solution.
Assay for signaling protein 
phosphorylation
Phosphorylation of signaling proteins, ERK1/2, p38 MAPK, 
and JNK, was analyzed with commercially available 
ELISA kits (Active Motif) according to the manufacturer’s 
  recommendation. In brief, cells treated with LPS and tiotro-
pium bromide were fixed with 4% formaldehyde for 20 min-
utes at 25°C. After washing the plate, the primary antibody 
against phosphorylated-ERK1/2, p38 MAPK, or JNK was 
added into each well at a volume of 40 µL and incubated for 
12 hours at 4°C. After removing the antibody by washing, 
100 µL of HRP-conjugated secondary antibody was added. 
After 1 hour at 25°C, tetramethylbenzyne solution was added 
at a volume of 100 µL per well and the absorbance at 450 nm 
was measured followed by the addition of 2 N HCl.
Statistical analysis
The statistical significance of the difference between control 
and experimental data was analyzed using a one-way analy-
sis of variance (ANOVA) test by using GraphPad Prism 5 
(GraphPad Software Inc, San Diego, CA). A P value ,0.05 
was accepted as statistically significant.
Results
Suppressive activity of tiotropium 
bromide on IL-8 production from cells 
after LPS stimulation
The first two experiments were designed to examine the 
influence of tiotropium bromide on LPS-induced IL-8 
  production from airway cells. BEAS-2B cells were   stimulated 
with 1.0 µg/mL LPS in the presence or absence of tiotropium 
bromide for 24 hours, and IL-8 levels in culture supernatants 
were assayed by ELISA. Although the addition of tiotropium 
Table 1 Primer sequences used for rT-PCr
Primer sequences Product   
size, bp
IL-8 
  Sense: 5′-ATgACTTCCAAgCTggCCgTggCT-3′ 
  Antisense: 5′-TCTCAgCCCTCTTCAAAAACTTCTC-3′
289
β-actin 
  Sense: 5′-ACCCACACTgTgCCCATCTA-3′ 
  Antisense: 5′ -CggAACCgCTCATTgCC-3′
239International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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bromide at concentration ,10.0 pg/mL could not inhibit the 
ability of cells to produce IL-8 in response to LPS stimulation, 
tiotropium bromide at 12.5 pg/mL significantly suppressed 
LPS-induced IL-8 production from BEAS-2B cells 
(Figure 1A). The data in Figure 1A also show that tiotropium 
bromide at concentration .15.0 pg/mL could completely 
inhibit IL-8 production from BEAS-2B cells in response to 
LPS stimulation: experimental culture supernatants contained 
similar levels of IL-8 to control culture supernatant. We then 
examined the influence of tiotropium bromide on LPS-induced 
IL-8 production from LFs. As shown in Figure 1B, tiotropium 
bromide also inhibited the ability of cells to produce IL-8 in 
response to LPS stimulation. The minimum concentration 
that caused significant suppression of IL-8 production was 
15.0 pg/mL (Figure 1B).
Suppressive activity of tiotropium 
bromide on IL-8 mrnA expression  
in cells after LPS stimulation
The third experiment was undertaken to examine the 
influence of tiotropium bromide on LPS-induced IL-8 mRNA 
expression in both BEAS-2B cells and LFs. BEAS-2B 
cells and LFs were stimulated with 1.0 µg/mL LPS in the 
presence of various concentrations of tiotropium bromide 
for 4 hours, and IL-8 mRNA expression was examined by 
RT-PCR. As shown in Figure 2A, the addition of tiotropium 
bromide at concentration .12.5 pg/mL significantly 
inhibited IL-8 mRNA expression, which was increased 
by LPS stimulation. Tiotropium bromide also inhibited 
IL-8 mRNA expression in LFs induced by LPS stimulation. 
The minimum concentration of tiotropium bromide that 
caused significant inhibition of IL-8 mRNA expression in 
LFs was 15.0 pg/mL (Figure 2B).
Suppressive activity of tiotropium  
bromide on transcription factor  
activation in cells after LPS stimulation
The fourth experiment was designed to examine the influence of 
tiotropium bromide on transcription factor, NF-κB, activation in 
both BEAS-2B cells and LFs. These cells were stimulated with 
1.0 µg/mL LPS in the presence of various concentrations of 
tiotropium bromide for 4 hours, respectively. The nuclear extract 
was prepared, and NF-κB activity was assessed by measuring 
p50 and p65 activity by ELISA. As shown in Figure 3, the 
addition of tiotropium bromide at concentration .12.5 pg/mL 
significantly suppressed p50 and p65 activation in BEAS-2B 
cells, which was increased by LPS stimulation. Figure 3 also 
shows the suppressive activity of tiotropium bromide on NF-κB, 
p50 and p65, activation induced by LPS stimulation in LFs 
(Figure 4). The minimum concentration that caused significant 
suppression was 15.0 pg/mL (Figure 4A and B).
Suppressive activity of tiotropium 
bromide on signaling protein 
phosphorylation
The fifth experiment was carried out to examine the influence 
of tiotropium bromide on signaling protein phosphorylation 
in both BEAS-2B cells and LFs after LPS stimulation. 
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Figure 1 Suppressive activity of tiotropium bromide (Tio) on IL-8 production from BeAS-2B cells (A) and lung fibroblasts (B) after lipopolysaccharide (LPS) stimulation. 
Cells (5 × 105 cells/mL) were stimulated with 1.0 µg/mL LPS in the presence of various concentrations of Tio for 24 hours. IL-8 levels in culture supernatants were examined 
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The cells were cultured with 1.0 µg/mL LPS in the presence of 
various concentrations of tiotropium bromide for 30 minutes. 
Signaling protein phosphorylation, p38MAPK, ERK1/2, 
and JNK, was examined by ELISA. Treatment of BEAS-2B 
cells with tiotropium bromide at concentration .12.5 pg/mL 
  significantly inhibited the phosphorylation of ERK1/2 and 
JNK but not p38 MAPK, which was enhanced by LPS 
stimulation (Figure 5A, B and C). Tiotropium bromide also 
significantly suppressed the phosphorylation of ERK1/2 and 
JNK but not p38MAPK in LPS-treated LFs, when cells were 
treated with tiotropium bromide at concentration .15.0 pg/mL 
(Figure 6A, B and C).
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Figure 2 Suppressive activity of tiotropium bromide (Tio) on IL-8 mrnA expression in BeAS-2B cells (A) and lung fibroblasts (B) after lipopolysaccharide (LPS) stimulation. 
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effect of kinase inhibitors on IL-8 
production from cells after LPS 
stimulation
The final experiment was performed to examine the role of 
signaling pathways regulating IL-8 production from both 
BEAS-2B cells and LFs after LPS stimulation. The cells were 
treated with kinase inhibitors, SP-600125, PD-98059, and 
SB-203580, 30 minutes before LPS stimulation. The culture 
supernatants were obtained after 24 hours and IL-8 levels 
were examined by ELISA. Pretreatment of cells, BEAS-2B 
(Figure 7A) and LFs (Figure 7B), with SP-600125 scarcely 
affected IL-8 production after LPS stimulation. On the other 
hand, pretreatment of cells with PD-98059 and SB-203580 
significantly suppressed IL-8 production from both BEAS-2B 
cells (Figure 7A) and LFs (Figure 7B).
Discussion
The present results clearly show that tiotropium bromide 
at concentration .15 pg/mL, which is extremely low 
  compared with therapeutic blood levels,15 could suppress 
IL-8 production from airway epithelial cells and LFs. In 
addition, this inhibitory action of tiotropium bromide on 
IL-8 production is due, in part, to its suppressive effect 
on IL-8 mRNA expression through the inhibition of both 
  transcription factor, NF-κB, activation and signaling protein 
phosphorylation, especially ERK1/2 and JNK, induced by 
LPS stimulation.
IL-8 is involved in several human diseases such as 
inflammation, angiogenesis, cancer metastasis, and COPD.16–18 
The primary function of IL-8 is also accepted to be the 
induction of chemotaxis in its target cells, especially 
neutrophils.9 Besides inducing chemotaxis, IL-8 is able to 
induce an increase in cytosolic calcium, which is essential 
for exocytosis (eg, mediator release), and respiratory burst.9 
Increased number of cells of the innate immune system is 
one important characteristic of inflammation in COPD.18 
There are mostly neutrophils, which are attracted as a result 
of mediator release by activated epithelial cells and resident 
cells of the monocyte/macrophage lineage at the alveoli and 
the small conducting airways.2,19,20 It has been suggested 
that chemokines, which attract neutrophils, act directly on 
fibroblasts and smooth muscle cells and promote airway 
remodeling observed in COPD.20 In addition, it is also reported 
that neutrophils infiltrated into airways and alveoli are activated 
to release neutrophil mediators such as myeloperoxidase and 
neutrophil lipocalin, which correlate broadly with disease 
severity.21–23 There is evidence that tiotropium bromide may 
have beneficial effects besides its bronchodilatory efficacy 
resulting in a decrease of chronic inflammation in COPD 
patients.13 Taken together, the present results may suggest 
that tiotropium bromide modulates favorably with the clinical 
conditions of COPD through the inhibition of neutrophil 
migration and activation by the suppression of IL-8 production 
from airway epithelial cells and lung fibroblasts.
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There is much evidence that central to the recognition 
of LPS expression in endothelial cells is a family of 
transmembrane proteins known as Toll-like receptors 
(TLRs).24–26 Most effector cells of the immune responses, 
especially the innate immune system, such as monocytes 
and endothelial cells express TLR2 and TLR4.27 When LPS 
binds to TLR4, multiple intracellular signaling pathways are 
activated, including transcription factor, NF-κB, pathway as 
well as MAPK.28 Three MAPK pathways, ERK, JNK, and 
p38 MAPK, contribute to IL-8 gene expression.29 ERK 
and p38 MAPK increase IL-8 gene expression in human 
bronchial cells.30 ERK can also activate NF-κB in human 
airway epithelial cells.31 Therefore, we then examined the 
possible mechanisms by which tiotropium bromide could 
inhibit LPS-induced IL-8 production from airway cells. The 
data clearly show that pretreatment of BEAS-2B cells and 
LFs decreased NF-κB activation induced by LPS   stimulation. 
It was also observed that tiotropium bromide could suppress 
phosphorylation of JNK and ERK1/2, but not p38 MAPK, 
which was increased by LPS stimulation. On the other hand, 
blocking experiments using MAPK pathway inhibitors 
showed evidence for the phosphorylation of ERK1/2 and p38 
MAPK, but not JNK in the production of IL-8 from BEAS-2B 
cells and LFs in response to LPS stimulation. Taken together, 
these results strongly suggest that tiotropium bromide inhibits 
IL-8 mRNA expression in BEAS-2B cells and LFs after 
LPS stimulation, which is responsible for inhibition of IL-8 
production at protein levels, through the suppression of the 
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activation of signal transducers and transcription factor, 
especially ERK1/2 and NF-κB. This speculation may be 
supported by the observation that pretreatment of 16HBE 
cells, a human bronchial epithelial cell line, with tiotropium 
bromide completely abolished IL-8 release induced by ace-
tylcholine stimulation through the suppression of ERK1/2 
and NF-κB activation.18
The activation of ERK1/2 signaling is regulated by 
cyclic adenosine monophosphate (cAMP),32 and elevation 
of cAMP levels in human bronchial epithelial cells increases 
IL-8 production.33 These reports may suggest that tiotropium 
bromide exerts the suppressive effect on the increase of 
cAMP by LPS stimulation in BEAS-2B cells and LFs. This 
speculation may be supported, in part, by the observation that 
muscarinic receptor antagonists, diphenidol and muscarinic 
toxin,7 blocked cAMP accumulation in both CHO-K1 cells 
after forskolin stimulation and rat striatal slices induced by 
muscarinic M1 receptor stimulation.34,35 On the other hand, 
stimulation of the TLR4 with LPS is reported to cause the 
activation of proline-rich tyrosine kinase, Pyk2, which is an 
essential intermediate providing a link between extracellular 
stimuli and signaling pathways involving MAPKs.36 It is also 
reported that, as a result of the interaction of LPS and TLR4 
on the cell surface, a signaling route is initiated via Pyk2 and 
MAPKs pathway leading to the production of IL-8 through 
NF-κB activation.26 These reports suggest the possibility 
that tiotropium bromide suppresses Pyk2 activation induced 
by LPS stimulation and results in the inhibition of IL-8 
production through the suppression of the Pyk2-mediated 
signaling pathway.
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Figure 6 Influence of tiotropium bromide (Tio) on signaling protein phosphorylation in lung fibroblasts after lipopolysaccharide (LPS) stimulation. Cells (5 × 105 cells/mL) 
were stimulated with 1.0 µg/mL LPS in the presence of various concentrations of Tio for 30 minutes. Signaling protein phosphorylation was examined by eLISA. The data 
are expressed as the mean optical density (OD) at 450 nm ± SE of five different subjects. (A) c-Jun n-terminal kinase (JnK) phosphorylation; (B) extracellular-signal-related 
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Suppression of IL-8 production by tiotropium bromide
In conclusion, the present data clearly show that 
tiotropium bromide suppresses LPS-induced release of IL-8 
from BEAS-2B cells as well as from LFs via the blockade of 
signaling pathways. This mechanism may possibly explain 
the therapeutic mode of action of tiotropium bromide on 
clinical conditions of patients with COPD.
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